Evaluate Safety and Efficacy of a Single Treatment Cycle of EB-001 in Subjects With Glabellar Frown Lines

Trial Profile

Evaluate Safety and Efficacy of a Single Treatment Cycle of EB-001 in Subjects With Glabellar Frown Lines

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Oct 2017

At a glance

  • Drugs Botulinum toxin E (Primary)
  • Indications Glabellar lines
  • Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
  • Sponsors Bonti
  • Most Recent Events

    • 09 Oct 2017 According to a Bonti media release, results were presented at Plastic Surgery The Meeting 2017 organized by the American Society of Plastic Surgeons (ASPS).
    • 13 Sep 2017 According to a Bonti media release, results from this study will be presented at the American Society for Dermatological Surgery (ASDS) Annual Meeting 2017.
    • 16 Aug 2017 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top